Maxime Frelaut

A blood-based epigenetic clock for intrinsic capacity predicts mortality and is associated with clinical, immunological and lifestyle factors - Nature Aging Fuentealba and colleagues build and validate a DNA methylation clock of intrinsic capacity (IC) to bridge resource-intensive clinical assessments of IC with molecular readouts of aging, highlighting s...

A new epigenetic clock —DNAmIC—outperforms others for identifying risk of all-cause mortality, and linked with lifestyle and immune system factors @nataging.nature.com
www.nature.com/articles/s43...

What You Should Know About RET-Positive NSCLC: Live from TexasLung25 | IASLC In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion live from the Texas Lung Cancer Conference with Dr. Mihaela Aldea about th ...

On #LungCancerConsidered this week, @narjustflorezmd.bsky.social & Dr. Mihaela Aldea talk about RET-positive NSCLC: diagnostic hurdles, treatment choices & more!

🎧 Tune in: bit.ly/TL25RET

#TexasLung25 #NSCLC

Creating a Mammography Conversation Aid for Shared Decision-Making Between Clinicians and Women Aged 75 and Older. #geriatrics #medsky agsjournals.onlinelibrary.wiley.com/doi/10.1111/...

Lien d'inscription : 6asl.r.ah.d.sendibm5.com/mk/cl/f/DMkh...

📢 Webinaire HOT d'OG @SOFOG @DIALOG
🧠 Machine Learning & modèle pronostique présenté par Étienne Audureau
📅 19 mai | 18h-19h
📄 D’après sa publication JCO janv 2025: pubmed.ncbi.nlm.nih.gov/39854651/
🔓 Gratuit sur inscription : lien ci-dessous
👉rejoignez-nous ! #gerionc #Oncogériatrie

For Oncology Residents
📅 ESMO Preceptorship on Cancer Care in Elderly Patients – May 8-9, 2025, Lugano
✅ Present your own geriatric oncology case
✅ Network with experts & peers across Europe
🔗 Apply now (deadline: March 27)
#Oncology #GeriatricOncology #ESMO #GeriOnc

Honored to present CABOLD study design at #ASCOGU25!
A prospective cohort assessing the feasibility of cabozantinib + nivolumab in m+ ccRCC for 70+ patients :
✅ Geriatric data at baseline & follow-up
✅ Enhanced monitoring
✅ Plasma monitoring of Cabo

#ASCOGU25 #KidneyCancer #OncoGeriatrics

Management of immune checkpoint inhibitor-associated toxicities in older adults with cancer: recommendations from the International Society of Geriatric Oncology (SIOG).

www.thelancet.com/journals/lan...

@thelancet.bsky.social @thelancetoncol.bsky.social @siogorg.bsky.social #GeriOnc

At #MAO2025, Dr. Camille Chakiba presented the PRIORITY study on cancer patients’ care goals:
📌 Key finding: Patients 70+ prioritize treatment efficacy, while oncologists emphasize toxicity risks more than patients themselves.
💡 Takeaway: Goals must be discussed case by case!
#Oncogeriatrics

📢 #MAO2025 | Chemo + IO in metastatic NSCLC for ≥65:
🔹 Meta-analysis (Dr. Emeline Orillard)
✅ Improved OS & PFS with IO in ≥65
❗ No significant benefit after 75 (small sample size)
📊 Update ongoing + need for raw data sharing.
#NSCLC #Immunotherapy #GeriatricOncology #MAO2025

🔬 ADC & elderly breast cancer patients 👵🎗️

At #MAO2025, experts highlighted:
✅ Efficacy signal in 65+ but limited data for older patients
⚠️ More toxicity & treatment discontinuation
🚀 Include elderly in innovation but with vigilance

#Oncogeriatrics #BreastCancer #ADC #CancerResearch

📢 Capucine Baldini at MAO 2025:
• ✅ No loss of efficacy of immunotherapy in older patients
• ❓ Immunosenescence impact? Still unclear
• 🔍 Need for prospective clinical & translational data

#MAO2025 #OncoGeriatrics #Immunotherapy

9.5% MET and 7.9% EGFR detected in pts w lung SqCC with no smoking history.

Important to improve testing in this group. We are finding more of this with reflex testing in early stage disease.

#lcsm

Systemic treatment among frail older patients with cancer: An observational cohort In the past, certain oncological therapies were not offered to frail older patients. However, the advancement of geriatric oncology, tailored chemotherapy regimens, the introduction of new treatments, and the optimization of supportive care have contributed to enhancing the therapeutic margin. We aimed to evaluate the benefit of systemic treatment among older adults by assessing the three-month survival of older frail patients with metastatic cancer.

🚨 Excited to share our work : "Systemic treatment among frail older patients with cancer".
✅ 3-month OS 81.8% when guided by geriatric assessments.
⚠️ Loss of ADL and cumulative frailty factors associated with poorer survival

🔗https://www.geriatriconcology.net/article/S1879-4068(24)00450-8/abstract

Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.

Can patterns of progression on IO, inform future decisions?

-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors

Prognostic, so far #LCSM

jamanetwork.com/journals/jam...

Time Toxicity of Systemic Anticancer Therapy for Metastatic Lung #Cancer in Routine Clinical Practice: A Nationwide Cohort Study.

ascopubs.org/doi/abs/10.1...

@ascocancer.bsky.social @ascopost.bsky.social
#CancerResearch #TimeToxicity #FinancialToxicity #CancerCare #LungCancer

At #SABCS24 LBA session - an EBCTCG meta-analysis explored immediate vs deferral surgery in women 70+ with operable breast cancer

Reduced local recurrence, distant recurrence and BC-mortality in the immediate surgery group

@oncoalert.bsky.social

Can gender & genetics impact alectinib tox? @jtoonline.bsky.social

- 215pts with ALK+ NSCLC
- women had ⬆️g3+ tox (f v m: 56% v 34% p=0.001), 35% had ⬆️trough levels p<0.001
- Pts with SNP affecting alectinib metabolism (PPAR-α 209G>A) had ⬆️g3+ tox

#Medsky #Oncsky #LCSM

www.jto.org/article/S155...